Lenvatinib (Lenvima®)

Assessment Status Rapid Review Complete
Drug Lenvatinib
Brand Lenvima®
Indication For the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine.
Assessment Process
Rapid review commissioned 05/05/2015
Rapid review completed 09/07/2015
Rapid review outcome Full pharmacoeconomic assessment recommended at the submitted price.

The HSE has approved reimbursement following confidential price negotiations. January 2016.